東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Phase II clinical development of new...

Ting, Naitee.

FindBook

Google Book

Amazon

博客來

Phase II clinical development of new drugs

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Phase II clinical development of new drugs/ by Naitee Ting ... [et al.].
其他作者:	Ting, Naitee.
出版者:	Singapore :Springer Singapore : : 2017.,
面頁冊數:	xvii, 241 p. :ill. (some col.), digital ;24 cm.
內容註:	Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials.
Contained By:	Springer eBooks
標題:	Drugs - Testing. -
電子資源:	http://dx.doi.org/10.1007/978-981-10-4194-5
ISBN:	9789811041945

Phase II clinical development of new drugs
Phase II clinical development of new drugs[electronic resource] /by Naitee Ting ... [et al.]. - Singapore :Springer Singapore :2017. - xvii, 241 p. :ill. (some col.), digital ;24 cm. - ICSA book series in statistics,2199-0980. - ICSA book series in statistics..

Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials.

This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.

ISBN: 9789811041945

Standard No.: 10.1007/978-981-10-4194-5doiSubjects--Topical Terms:

646233
Drugs
--Testing.

LC Class. No.: RM301.27

Dewey Class. No.: 615.580724

Phase II clinical development of new drugs
LDR:02082nmm a2200337 a 4500 001 2097702
003 DE-He213
005 20170412095616.0
006 m d
007 cr nn 008maaau
008 171229s2017 si s 0 eng d
020 $a 9789811041945 $q (electronic bk.)
020 $a 9789811041921 $q (paper)
024 7 $a 10.1007/978-981-10-4194-5 $2 doi
035 $a 978-981-10-4194-5
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.27
072 7 $a PBT $2 bicssc
072 7 $a MBNS $2 bicssc
072 7 $a MED090000 $2 bisacsh
082 0 4 $a 615.580724 $2 23
090 $a RM301.27 $b .P536 2017
245 0 0 $a Phase II clinical development of new drugs $h [electronic resource] / $c by Naitee Ting ... [et al.].
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2017.
300 $a xvii, 241 p. : $b ill. (some col.), digital ; $c 24 cm.
490 1 $a ICSA book series in statistics, $x 2199-0980
505 0 $a Chapter 1 Introduction -- Chapter 2 Concept of Alpha -- Chapter 3 Confirmation and Exploration -- Chapter 4 Design a Proof of Concept (PoC) Trial -- Chapter 5 Design of Dose-Ranging Trials -- Chapter 6 Combining PoC and Dose Ranging Trials -- Chapter 7 Risks of Inconclusiveness -- Chapter 8 Analysis of a PoC Study -- Chapter 9 Data Analysis for Dose-Ranging Trials with Continuous Outcome -- Chapter 10 Data Analysis of Dose-Ranging Trials for Binary Outcomes -- Chapter 11 Bayesian Methods -- Chapter 12 Overview of Phase III Clinical Trials.
520 $a This book focuses on how to appropriately plan and develop a Phase II program, and how to design Phase II clinical trials and analyze their data. It provides a comprehensive overview of the entire drug development process and highlights key questions that need to be addressed for the successful execution of Phase II, so as to increase its success in Phase III and for drug approval. Lastly it warns project team members of the common potential pitfalls and offers tips on how to avoid them.
650 0 $a Drugs $x Testing. $3 646233
650 0 $a Drug development. $3 716904
650 1 4 $a Statistics. $3 517247
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 891086
650 2 4 $a Pharmaceutical Sciences/Technology. $3 1001579
650 2 4 $a Management. $3 516664
700 1 $a Ting, Naitee. $3 2184875
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a ICSA book series in statistics. $3 2153476
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-4194-5
950 $a Mathematics and Statistics (Springer-11649)